PE20040564A1 - Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion y medicamentos que comprenden estos compuestos - Google Patents

Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion y medicamentos que comprenden estos compuestos

Info

Publication number
PE20040564A1
PE20040564A1 PE2003000596A PE2003000596A PE20040564A1 PE 20040564 A1 PE20040564 A1 PE 20040564A1 PE 2003000596 A PE2003000596 A PE 2003000596A PE 2003000596 A PE2003000596 A PE 2003000596A PE 20040564 A1 PE20040564 A1 PE 20040564A1
Authority
PE
Peru
Prior art keywords
compounds
diphenylazetidinones
medicines
substituted
procedure
Prior art date
Application number
PE2003000596A
Other languages
English (en)
Spanish (es)
Inventor
Stefanie Flohr
Wendelin Frick
Heiner Glombik
Hans-Ludwig Schaefer
Gerhard Jaehne
Werner Kramer
Andreas Lindenschmidt
Hubert Heuer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20040564A1 publication Critical patent/PE20040564A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/568Four-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2003000596A 2002-06-19 2003-06-16 Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion y medicamentos que comprenden estos compuestos PE20040564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10227508A DE10227508A1 (de) 2002-06-19 2002-06-19 Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Publications (1)

Publication Number Publication Date
PE20040564A1 true PE20040564A1 (es) 2004-10-25

Family

ID=29719283

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000596A PE20040564A1 (es) 2002-06-19 2003-06-16 Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion y medicamentos que comprenden estos compuestos

Country Status (28)

Country Link
EP (1) EP1517891B1 (https=)
JP (1) JP2005533073A (https=)
KR (1) KR20050008835A (https=)
CN (1) CN100467448C (https=)
AR (1) AR039690A1 (https=)
AU (1) AU2003238210B2 (https=)
BR (1) BR0311896A (https=)
CA (1) CA2490112A1 (https=)
DE (1) DE10227508A1 (https=)
EC (1) ECSP045497A (https=)
HN (1) HN2003000185A (https=)
HR (1) HRPK20041201B3 (https=)
IL (1) IL165789A0 (https=)
MA (1) MA27206A1 (https=)
MX (1) MXPA04012093A (https=)
NO (1) NO20050134L (https=)
OA (1) OA12869A (https=)
PA (1) PA8576101A1 (https=)
PE (1) PE20040564A1 (https=)
PL (1) PL372700A1 (https=)
RS (1) RS108404A (https=)
RU (1) RU2287522C2 (https=)
SV (1) SV2004001548A (https=)
TN (1) TNSN04250A1 (https=)
TW (1) TW200413311A (https=)
UA (1) UA78577C2 (https=)
UY (1) UY27853A1 (https=)
WO (1) WO2004000805A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
US8361999B2 (en) 2005-04-04 2013-01-29 Pontificia Universidad Catolica De Chile Methods of treating cholesterol gallstone disease with ezetimibe
DE602006010870D1 (de) 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
CN103382174A (zh) * 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101200443B (zh) * 2007-10-17 2011-06-29 中国药科大学 氮杂环丁酮衍生物、其制备方法及含有它们的药物组合
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
AU2002231688A1 (en) * 2000-12-21 2002-07-01 Sanofi-Aventis Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
HRP20030498A2 (en) * 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism

Also Published As

Publication number Publication date
HN2003000185A (es) 2005-10-20
NO20050134D0 (no) 2005-01-11
JP2005533073A (ja) 2005-11-04
MXPA04012093A (es) 2005-04-19
NO20050134L (no) 2005-03-18
HRP20041201A2 (en) 2005-08-31
PA8576101A1 (es) 2004-02-07
AU2003238210A1 (en) 2004-01-06
RU2287522C2 (ru) 2006-11-20
BR0311896A (pt) 2005-04-05
IL165789A0 (en) 2006-01-15
AR039690A1 (es) 2005-03-09
UA78577C2 (en) 2007-04-10
HRPK20041201B3 (en) 2006-12-31
CA2490112A1 (en) 2003-12-31
TW200413311A (en) 2004-08-01
CN1662495A (zh) 2005-08-31
AU2003238210B2 (en) 2008-10-23
ECSP045497A (es) 2005-03-10
DE10227508A1 (de) 2004-01-08
TNSN04250A1 (en) 2007-03-12
KR20050008835A (ko) 2005-01-21
HK1079511A1 (zh) 2006-04-07
RS108404A (sr) 2007-02-05
EP1517891B1 (de) 2013-04-03
EP1517891A1 (de) 2005-03-30
PL372700A1 (en) 2005-07-25
WO2004000805A1 (de) 2003-12-31
MA27206A1 (fr) 2005-01-03
RU2005101093A (ru) 2005-07-20
SV2004001548A (es) 2004-03-19
CN100467448C (zh) 2009-03-11
OA12869A (en) 2006-09-15
UY27853A1 (es) 2003-12-31

Similar Documents

Publication Publication Date Title
PE20040564A1 (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion y medicamentos que comprenden estos compuestos
RU2409562C2 (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
RU2409572C2 (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
RU2370485C2 (ru) Амидоацетонитрильные производные
RU2002118334A (ru) Пиразолкарбоксамидные и пиразолтиоамидные производные в качестве фунгицидов
PE20030547A1 (es) Derivados de imidazol para el tratamiento de la obesidad
EE200300464A (et) Protsess asetidinoonvaheühendite valmistamiseks ja asetidinoonvaheühend
DK0526434T3 (da) Benzimidazolonderivater som 5-HT1A- og 5-HT2-antagonister
PE20011067A1 (es) Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas
ES2168396T3 (es) 4-(fenilo sustituido con (heterocicloalquilo o heteroaromatico))-2-azetidinonas utiles como agentes hipolipidemicos.
PE20090992A1 (es) Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa
BR9202219A (pt) Compostos e processo para sua preparacao,composicoes farmaceuticas e uso dos ditos compostos
NO955256L (no) Fenylheterosykluser som syklooksygenase-2-inhibitorer
PE20010168A1 (es) Sal mutua de amlodipino y atorvastatina
EA200400674A1 (ru) Соли e-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил)аллил)ацетамида, их получение и их применение против рака
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
NO20054791L (no) Forbindelser for behandling av stoffskiftesykdommer
CO5670350A2 (es) Proceso para preparar derivados de acido 5-(1,3-oxazol- 2-il) benzoico
EE200200591A (et) Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks
PE20011008A1 (es) Derivados de pirimidina como inhibidores de ciclooxigenasa 2
ATE66915T1 (de) Dihydropyridine.
SE8702330L (sv) Foreningar avsedda att anvendas som mellanprodukt for framstellning av 3-amino-2-oxo-azetidin-1-sulfonsyror
PE20010169A1 (es) Profarmacos mutuos de amlodipino y atorvastatina
MX2007005137A (es) Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed